RAPS and China’s SFDA form regulatory education and training collaboration

Published: 9-Nov-2012
Training & Education Regulatory

Initial focus will be on medical device regulation


The Regulatory Affairs Professionals Society (RAPS) is to collaborate with China’s State Food and Drug Administration Institute of Executive Development (SFDAIED) on regulatory training and education in China and the US.

RAPS is a global organisation for those involved with the regulation of healthcare and related products, based in Rockville, MD, US. SFDAIED is the branch of China’s SFDA that provides education and training to the country’s regulatory authorities and professionals overseeing food, drugs and other healthcare products.

The two organisations have signed a Memorandum of Understanding and agree that the priority focus area should be on medical devices. They will work together to develop an international workshop on medical device regulation, as well as integrate RAPS’ training programmes into SFDAIED’s and develop training on Chinese medical device regulation for RAPS’ global web-based training programme, RAPS Online University.

‘Healthcare products and medical technology are developed, manufactured and marketed all across the world today. These products and the work that goes into creating them and making them available is not confined within national boundaries, and neither should the best training and resources be for those who regulate them,’ said RAPS’ executive director Sherry Keramidas.

‘This collaboration will help regulatory professionals in industry and government in China and the US to further their regulatory knowledge, building global regulatory capacity that can help improve public health for the people of both nations and beyond.’

  • Companies:
  • RAPS Regulatory Affairs Professionals Society
See more

You may also like

Regulatory

USP and British counterpart join forces

Read more
Pharmacopoeias in the US and in the UK have signed a memorandum of understanding to strengthen quality standards for medicines

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

USP and British counterpart join forces

Pharmacopoeias in the US and in the UK have signed a memorandum of understanding to strengthen quality standards for medicines
Regulatory

RAPS Europe Conference 2019 to address sweeping changes in European regulatory environment

The event in May comes as a host of new laws affecting the medicines, medical devices and <em>in vitro</em> diagnostics (IVDs) sectors are due to come into effect
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

RAPS publishes compensation survey of regulatory professionals

Offering a look at how much healthcare product regulatory professionals earn, which products they work on, what their work entails and how their roles have evolved
Regulatory

MPs back amendment to keep UK in EU medicines regulatory network

Industry insiders comment on disruptions to the supply of medicines post-Brexit and what the MPs backed amendment means for British patients
Regulatory

Brexit and healthcare product regulation

Navigating the grey
Training & Education

Addressing the regulatory skills gap

In a role that is so critical to the quality and compliance of pharmaceutical products across the globe, what can companies do to close the growing skills gap?
Subscribe now